JG
ACAD icon

Joel Greenblatt’s Acadia Pharmaceuticals ACAD Stock Holding History

Joel Greenblatt’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,358
Closed -$898K – 1793
2026
Q1 		$898K Buy
40,358
+21,917
+119% +$524K ﹤0.01% 1342
2025
Q4 		$493K Sell
18,441
-24,726
-57% -$591K ﹤0.01% 1443
2025
Q3 		$921K Buy
43,167
+25,560
+145% +$604K ﹤0.01% 1224
2025
Q2 		$380K Sell
17,607
-16,467
-48% -$306K ﹤0.01% 1397
2025
Q1 		$566K Sell
34,074
-35,892
-51% -$652K ﹤0.01% 1198
2024
Q4 		$1.28M Buy
69,966
+34,240
+96% +$553K 0.01% 839
2024
Q3 		$549K Buy
35,726
+5,129
+17% +$85.6K 0.01% 1079
2024
Q2 		$497K Buy
+30,597
New +$494K 0.01% 1084
2020
Q2 		– Sell
-6,975
Closed -$295K – 1045
2020
Q1 		$295K Sell
6,975
-8,683
-55% -$358K 0.01% 843
2019
Q4 		$670K Sell
15,658
-12,364
-44% -$538K 0.01% 718
2019
Q3 		$1.01M Buy
+28,022
New +$850K 0.02% 592
2017
Q4 		– Sell
-38,843
Closed -$1.46M – 921
2017
Q3 		$1.46M Buy
+38,843
New +$1.26M 0.02% 559
2017
Q1 		– Sell
-25,682
Closed -$741K – 977
2016
Q4 		$741K Buy
+25,682
New +$679K 0.01% 675

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Joel Greenblatt's ACAD Position: Q2 2026 in Review

Joel Greenblatt sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 40,358 shares — an estimated $898K sold.

Joel Greenblatt first reported a position in ACAD in Q4 2016 and held it in 13 quarters. The position peaked at $1.46M in Q3 2017. 350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Joel Greenblatt reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Joel Greenblatt sold 40,358 Acadia Pharmaceuticals shares in Q2 2026, an estimated $898K.
  • Joel Greenblatt first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 13 quarters.
  • Joel Greenblatt's Acadia Pharmaceuticals position peaked at $1.46M in Q3 2017.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.